Devasmita Sen, Sristi Datta, Srija Biswas, Asmita Samadder, Sisir Nandi
{"title":"利用益生元、后益生菌和合成菌治疗调节肠道微生物群以对抗异常细胞信号传导介导的胃肠道癌症。","authors":"Devasmita Sen, Sristi Datta, Srija Biswas, Asmita Samadder, Sisir Nandi","doi":"10.2174/0115680096373099250709100217","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal (GI) cancer, a multifactorial disease, encompasses a group of malignancies that affect the gastrointestinal system. Being the second leading con-tributor to cancer-related deaths, GI cancer has become the burning issue of human health. Despite advances in treatment, the diverse nature of GI cancer indicates that a one-size-fits-all solution is not applicable.</p><p><strong>Introduction: </strong>The gut microbiome can be therapeutically modulated by utilizing prebiotics, postbiotics, and synbiotics. Fermentation of prebiotics produces postbiotic compounds. To-gether the prebiotics and probiotics combination can be used as synbiotics which will be more beneficial.</p><p><strong>Methods: </strong>PubMed and Google scholar search engine tools have been utilized to access ref-erences about the idea of this review to demonstrate the therapeutic modulation of microbiota, residing in the gut, which utilizes postbiotics, prebiotics and synbiotics for combating GI cancer.</p><p><strong>Results: </strong>Exploration of prebiotics, postbiotics, and synbiotic compounds has given us de-tailed information about their contribution to combating GI cancer.</p><p><strong>Conclusion: </strong>Intake of a combination of prebiotic, postbiotics and synbiotics can inhibit the growth of cancer cells, and activate protective and stress-resistant mechanisms in healthy cellswhich couldbe more beneficial than the administration of prebiotics or postbiotics or synbiotics alone in diminishing the risk of GI cancer.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"To Combat Abnormal Cell Signaling Mediated Gastrointestinal Cancer by Therapeutic Modulation of Gut Microbiota Utilizing Prebiotics, Postbiotics, and Synbiotics.\",\"authors\":\"Devasmita Sen, Sristi Datta, Srija Biswas, Asmita Samadder, Sisir Nandi\",\"doi\":\"10.2174/0115680096373099250709100217\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Gastrointestinal (GI) cancer, a multifactorial disease, encompasses a group of malignancies that affect the gastrointestinal system. Being the second leading con-tributor to cancer-related deaths, GI cancer has become the burning issue of human health. Despite advances in treatment, the diverse nature of GI cancer indicates that a one-size-fits-all solution is not applicable.</p><p><strong>Introduction: </strong>The gut microbiome can be therapeutically modulated by utilizing prebiotics, postbiotics, and synbiotics. Fermentation of prebiotics produces postbiotic compounds. To-gether the prebiotics and probiotics combination can be used as synbiotics which will be more beneficial.</p><p><strong>Methods: </strong>PubMed and Google scholar search engine tools have been utilized to access ref-erences about the idea of this review to demonstrate the therapeutic modulation of microbiota, residing in the gut, which utilizes postbiotics, prebiotics and synbiotics for combating GI cancer.</p><p><strong>Results: </strong>Exploration of prebiotics, postbiotics, and synbiotic compounds has given us de-tailed information about their contribution to combating GI cancer.</p><p><strong>Conclusion: </strong>Intake of a combination of prebiotic, postbiotics and synbiotics can inhibit the growth of cancer cells, and activate protective and stress-resistant mechanisms in healthy cellswhich couldbe more beneficial than the administration of prebiotics or postbiotics or synbiotics alone in diminishing the risk of GI cancer.</p>\",\"PeriodicalId\":10816,\"journal\":{\"name\":\"Current cancer drug targets\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current cancer drug targets\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0115680096373099250709100217\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096373099250709100217","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
To Combat Abnormal Cell Signaling Mediated Gastrointestinal Cancer by Therapeutic Modulation of Gut Microbiota Utilizing Prebiotics, Postbiotics, and Synbiotics.
Background: Gastrointestinal (GI) cancer, a multifactorial disease, encompasses a group of malignancies that affect the gastrointestinal system. Being the second leading con-tributor to cancer-related deaths, GI cancer has become the burning issue of human health. Despite advances in treatment, the diverse nature of GI cancer indicates that a one-size-fits-all solution is not applicable.
Introduction: The gut microbiome can be therapeutically modulated by utilizing prebiotics, postbiotics, and synbiotics. Fermentation of prebiotics produces postbiotic compounds. To-gether the prebiotics and probiotics combination can be used as synbiotics which will be more beneficial.
Methods: PubMed and Google scholar search engine tools have been utilized to access ref-erences about the idea of this review to demonstrate the therapeutic modulation of microbiota, residing in the gut, which utilizes postbiotics, prebiotics and synbiotics for combating GI cancer.
Results: Exploration of prebiotics, postbiotics, and synbiotic compounds has given us de-tailed information about their contribution to combating GI cancer.
Conclusion: Intake of a combination of prebiotic, postbiotics and synbiotics can inhibit the growth of cancer cells, and activate protective and stress-resistant mechanisms in healthy cellswhich couldbe more beneficial than the administration of prebiotics or postbiotics or synbiotics alone in diminishing the risk of GI cancer.
期刊介绍:
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.
Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.